Dr. Timothy Garrington is a pediatric oncologist with a clinical focus in solid tumors, particularly bone tumors, soft tissue sarcomas, germ cell tumors, and histiocytic disorders. He also has a major interest in medical education and research on methods to improve teaching of medical students and physicians. Dr. Garrington is a Course Director in the Medical School and also directs the CCBD Pediatric Hematology/Oncology Fellowship Training Program.
Dr. Roger Giller is engaged in clinical research pertaining to allogeneic hematopoietic stem cell transplantation (HSCT). He directs clinical trials that seek to define the role of HSCT for treatment of children and adolescents with cancer and nonmalignant disorders. Dr. Giller also has a special interest in and conducts clinical trials related to viral infections in immunocompromised hosts.
Dr. Neil Goldenberg studies blood clotting and thrombotic disorders. He is the Associate Director of the Mountain States Regional Hemophilia and Thrombosis Center and he developed and is Co-Director of the Colorado Pediatric Stroke Program at Children’s Hospital Colorado, a unique multidisciplinary program based both in the CCBD and the Child Neurology Section. He is the Director of Clinical Safety and venous thromboembolism trials at CPC Clinical Research. He is also the Co-chair of the recently-formed Antithrombotic Trials Leadership and Steering (ATLAS) group.
Dr. Lia Gore founded and directs the CCBD Pediatric Experimental Therapeutics Program (ETP), which is dedicated to development and clinical testing of new treatments for children and adolescents with cancer who have not responded to standard therapies. Dr. Gore is the co-founder and co-director of the Pediatric Experimental Therapeutics Investigator Consortium (POETIC), which includes eleven major pediatric oncology programs from the U.S. and Canada. She also is a member of the Developmental Therapeutics Program at The University of Colorado Cancer Center and directs the Early Phase Hematological Maligancies program there. Dr. Gore participates in clinical research in Acute Lymphoblastic Leukemia (ALL) through the Children’s Oncology Group (COG) and has active collaborations in the UK, Europe and Australia related to pediatric oncology drug development.
Dr. Douglas Graham directs a research lab that studies the MER family of receptor tyrosine kinases and it is involved in development of cancer and clotting disorders. His lab has shown that interfering with the function of MER protein can potentiate chemotherapy in leukemia and lung cancer and is developing new therapies directed at MER. In addition, his laboratory is testing novel biologic inhibitors of MER as a strategy to block platelet activation and prevent thrombus formation. Dr. Graham is also the co-principal investigator of our NIH-funded T32 grant to train pediatric cancer researchers.
Dr. Brian Greffe has a research focus on survivorship and the late effects of cancer treatment. He is also board certified in palliative care and engages in research related to pediatric palliative and hospice care.
Dr. Taru Hays is engaged in research studies in pediatric blood disorders. She is the co-author of a new textbook on pediatric blood cell morphology.
Dr. Stephen Hunger is an internationally recognized expert in leukemia genetics and the treatment of childhood Acute Lymphoblastic Leukemia (ALL). Dr. Hunger serves as Chair of the COG ALL Disease Committee, which is responsible for the design and conduct of clinical trials and linked laboratory research studies that include over 70% of U.S. and Canadian children with ALL. He is a co-author on over 100 peer-reviewed scientific manuscripts, and is Principal Investigator or Co-Investigator on a number of NIH grants. Dr. Hunger’s clinical interests focus on treatment of children with leukemia and lymphoma, and on cancer predisposition syndromes. Dr. Hunger and Dr. Douglas Graham are Co-Principal Investigators of an NIH-funded T32 grant to train pediatric cancer researchers.
Dr. Amy Keating studies the role of the MER family of receptor tyrosine kinases in malignancy. Currently she and members of her laboratory are investigating how astrocytic brain tumors grow, survive following chemotherapy and radiation treatment, and migrate throughout the brain. By recognizing and characterizing how astrocytoma cells accomplish these processes, she hopes to develop new therapies that work better and are safer for our young patients.